Liquidia Corporation (LQDA)

Liquidia Corp. stock has experienced significant events and positive momentum in the past six months. The FDA approved Yutrepia, leading to an exceptional commercial launch with over 2,000 unique prescriptions and shipments to more than 1,500 patients. The company reported strong financial performance in Q3 2025, with total revenues of $54 million, a 1,134% year-over-year increase, and narrowed its net loss by 89% to $3.5 million. Liquidia generated more than $30 million of positive cash flow during the fourth quarter of 2025. The share price rose to $22.74 at the end of Q3 2025 and hit a new 52-week high of $46.67 on February 3, 2026. Several analysts have raised their price targets for Liquidia, with a consensus rating of "Moderate Buy." Litigation with United Therapeutics regarding patent infringement remains an ongoing factor.

Based on the available information, there is no explicit mention of demand seasonality for Liquidia Corp.'s products and services. Given that Yutrepia is a treatment for chronic conditions, significant seasonality in demand might not be a primary characteristic of their market.

Liquidia Corporation is a biopharmaceutical company based in Morrisville, North Carolina, focused on developing, manufacturing, and commercializing innovative therapies for patients with rare cardiopulmonary diseases, primarily in the United States. The company operates within the Healthcare sector and the Biotechnology industry, leveraging its PRINT technology to produce uniform drug particles. Its major products include YUTREPIA (treprostinil) inhalation powder, Remodulin, and L606 (liposomal treprostinil inhalation suspension).

Liquidia Corporation primarily focuses its development, manufacturing, and commercialization efforts on products for unmet patient needs principally in the United States. The company's headquarters are located in Morrisville, North Carolina.

Liquidia Corp. has a strong brand reputation, driven by the successful launch of Yutrepia, indicated by its exceptional commercial launch and enthusiasm from prescribers and patients. Analyst ratings skew heavily towards optimism, with a consensus of "Moderate Buy." However, ongoing patent litigation with United Therapeutics represents a potential reputational risk.

Liquidia Corporation's stock is distributed among institutional, retail, and individual investors. Approximately 80.65% of the company's common stock is held by other institutional investors, and 13.88% by mutual funds & ETFs. Public companies and retail investors own about 5.47% of the shares, and insiders own approximately 22.66% of the stock. Major institutional owners include Farallon Capital Management Llc, Caligan Partners LP, BlackRock, Inc., Vanguard Group Inc, Findell Capital Management Llc, Goldman Sachs Group Inc, Opaleye Management Inc., Susquehanna International Group, Llp, and Point72 Asset Management, L.P.